Soligenix announced today that it will be presenting preclinical data from three of its biodefense programs at the upcoming Chemical and Biological Defense Science and Technology Conference on May 12-14, 2015 in St. Louis, Mo.
The presented results will address recent preclinical efficacy findings in three programs, including:
- SGX943 in the treatment of antibiotic resistant infections including melioidosis
- RiVax, a proprietary thermostable ricin toxin vaccine, in an inhalational model of ricin intoxication, and
- VeloThrax, a proprietary thermostable anthrax toxin vaccine.
SGX943 is based on Soligenix’s SGX94 technology, an Innate Defense Regulator, which enhances the anti-infective activity of the innate immune system while modulating inflammation. Since SGX943 does not directly target the bacteria, it is unlikely to engender resistance and is complementary with current antibiotic regimens.
RiVax is the company’s candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. When formulated with Soligenix’s proprietary ThermoVax technology, RiVax has demonstrated significantly enhanced thermostability and 100% protection in preclinical aerosol challenge models.
VeloThrax is the company’s candidate vaccine for the prevention of exposure to anthrax using the Dominant Negative Inhibitor (DNI) of the recombinant protective antigen (rPA) of anthrax. When formulated with Soligenix’s proprietary ThermoVax technology, VeloThrax has demonstrated significantly enhanced thermostability and compatibility with secondary adjuvants such as TLR-4 agonists, facilitating more rapid onset of immunity.
Preclinical studies for SGX943, RiVax, and VeloThrax were supported by grant awards from the National Institute of Allergy and Infectious Diseases (NIAID).
Oral and poster presentations involving Soligenix products include:
- Innate Defense Regulators as Adjunctive Treatments for Antibiotic Resistant Infections presented by Dr. Oreola Donini, Chief Scientific Officer, Soligenix, Inc.
- Thermostable Subunit Vaccine Results in Protective Immunity in Rhesus Macaques in an Inhalational Ricin Model attended by Dr. Chad Roy, Director, Infectious Disease Aerobiology, Tulane National Primate Research Center, Associate Professor of Microbiology & Immunology, Tulane School of Medicine
- Stability, Efficacy and Immunogenicity of a Third Generation Heat-Stable Anthrax Subunit Vaccine attended by Dr. Oreola Donini, Chief Scientific Officer, Soligenix, Inc.
The CBD S&T Research Conference is a forum for discussion between individuals conducting research to defend against bioterrorism and with the Defense Threat Reduction Agency (DTRA). Areas of specific interest include disease surveillance, characterization and point of need diagnostics, adaptive medical therapeutics and technology, rapid response and recovery science and technology and threat activity sensing and reporting. The conference offers business, learning and networking opportunities in the biodefense arena.
